Loading
LigaChem Biosciences
LigaChem Biosciences is a South Korea-based biotechnology company running 2 late-stage cancer trials of LCB02A and LCB84.
Also called: LigaChem Biosciences, Inc.
Overview
LigaChem Biosciences, based in Daejeon, South Korea, is a biotechnology company. LigaChem Biosciences is a biotech company focused on drug research and development, specialising in antibody-drug conjugate (ADC) therapeutics, small molecule immunotherapies and synthetic drug development. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LCB02A and LCB84. The largest, NCT05941507 (A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumours), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Daejeon, KR
Scorecard
All companies#315of 1245 companies, score 13
- phase 1/2 +2
- targets +4
- modalities +4
- registry trials +3
0 approved, 0 in phase 3, 2 earlier, 2 targets, 2 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Products
2Phase 2monoclonal antibody
LCB02A is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at Claudin 18.2.
Phase 2ADC
LCB84 is an experimental antibody-drug conjugate from LigaChem Biosciences. It links an antibody aimed at TROP2 to an MMAE prodrug and is being studied in a phase 1/2 trial.
Connected
4Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
ligachembio.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/